bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
All Web sites
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2013: M A M F J
2012: D N O S A J J M

 
  Other news for:
Alzheimer Disease
Brain
Parkinson Disease
 Resources from HONselect
Discovery May Improve Diagnosis of Alzheimer's, Parkinson's
Markers in cerebrospinal fluid might help distinguish different forms of neurological disease, study finds

By Robert Preidt

WEDNESDAY, Aug. 29 (HealthDay News) -- Four indicators, or "biomarkers," found in cerebrospinal fluid can help differentiate patients with Alzheimer's disease from those with other forms of dementia, and a different biomarker can distinguish patients with Parkinson's disease from those with parkinsonian disorders, researchers say.

Overlapping symptoms, especially in the early stages, can make it difficult to distinguish between regular Parkinson's disease and atypical Parkinsonism, and also between Alzheimer's disease and other forms of dementia, the study authors explained.

The investigators identified the five biomarkers by analyzing cerebrospinal fluid samples from 453 patients with Parkinson's, Parkinson's disease with dementia, Alzheimer's and other forms of dementia.

"Together with earlier published data, our results indicate that these five [cerebrospinal fluid] biomarkers might have clinical value in the differential diagnosis of dementia and/or parkinsonism," concluded Dr. Sara Hall, of Skane University Hospital in Sweden, and colleagues.

The study was published online Aug. 27 in the journal Archives of Neurology.

The findings represent "a significant step forward, demonstrating how a relatively modest panel of robust [cerebrospinal fluid] protein biomarkers can categorize dementias and parkinsonian syndromes on the basis of pathology rather than clinical/behavioral changes," Dr. Richard Perrin, of the Washington University School of Medicine in St. Louis, wrote in an accompanying editorial.

The use of these indicators in cerebrospinal fluid could improve the efficiency of clinical trials and speed up the development and evaluation of new treatments for neurological diseases, Perrin concluded.

More information

The National Parkinson Foundation has more about atypical Parkinsonism.

SOURCE: Archives of Neurology, news release, Aug. 27, 2012

Copyright © 2012 HealthDay. All rights reserved. URL:http://www.healthscout.com/template.asp?id=667992

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Diagnosis
Dementia
Parkinsonian Disorders
Research Personnel
Alzheimer Disease
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img MediaCorner img HON newsletter img Site map img Ethical policies img Contact